WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo

MA Markus, B Heinrich, O Raitskin, DJ Adams… - Experimental cell …, 2006 - Elsevier
MA Markus, B Heinrich, O Raitskin, DJ Adams, H Mangs, C Goy, M Ladomery, R Sperling
Experimental cell research, 2006Elsevier
Wilm's tumor protein 1 (WT1), a protein implicated in various cancers and developmental
disorders, consists of two major isoforms: WT1 (− KTS), a transcription factor, and WT1 (+
KTS), a post-transcriptional regulator that binds to RNA and can interact with splicing
components. Here we show that WT1 interacts with the novel splicing regulator RBM4. Each
protein was found to colocalize in nuclear speckles and to cosediment with
supraspliceosomes in glycerol gradients. RBM4 conferred dose-dependent and cell-specific …
Wilm's tumor protein 1 (WT1), a protein implicated in various cancers and developmental disorders, consists of two major isoforms: WT1(−KTS), a transcription factor, and WT1(+KTS), a post-transcriptional regulator that binds to RNA and can interact with splicing components. Here we show that WT1 interacts with the novel splicing regulator RBM4. Each protein was found to colocalize in nuclear speckles and to cosediment with supraspliceosomes in glycerol gradients. RBM4 conferred dose-dependent and cell-specific regulation of alternative splicing of pre-mRNAs transcribed from several reporter genes. We found that overexpressed WT1(+KTS) abrogated this effect of RBM4 on splice-site selection, whereas WT1(−KTS) did not. We conclude that the (+KTS) form of WT1 is able to inhibit the effect of RBM4 on alternative splicing.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果